Growblox Sciences Inc (OTCMKTS:GBLX) has been moving up over $0.20 support in recent days. The stock popped earlier this year as well as at the end of last year during the last mj rush to highs of $0.65.
GBLX started trading as Growblox Sciences Inc in April of last year after the name change from Signature Exploration and Production Corp.
Growblox Sciences Inc (OTCMKTS:GBLX) is a biotechnology research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.
GB Sciences’ pioneering self-contained growing unit isolates and protects the plants growing inside while generating ideal growing environments to ensure high quality, purity, and consistency.
TissueBLOX™ – The tissue culture incubator is programmed to regulate lighting, temperature, and humidity to facilitate cell multiplication and the formation of embryos and shoots from the sterile explants.
GrowBLOX™ – GB Sciences’ pioneering self-contained growing unit that isolates and protects the plants growing inside while generating ideal growing environments
CureBLOX™ – The CureBLOX™ module enables us to eliminate the risk of mold growth and ensure that the chemical profile of our products is consistent from harvest to harvest.
GB Sciences ApotheCAREians – Highly trained and certified ApotheCAREians work with patients to determine their medical needs, identify therapeutic products, install GB Sciences’ app on their hand-held devices, and demonstrate how to place orders.
To Find out the inside Scoop on GBLX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
ApotheCAREians are patient-care professionals who know more about cannabinoid therapy than most physicians, since doctors are rarely trained in cannabinoid therapy. They understand the science of cannabis and can help patients choose the cannabinoid therapy products that will provide the most effective treatment for their particular medical conditions.
On may 23 GBLX announced the filing of its latest patent application by its wholly-owned subsidiary, Growblox Life Sciences, LLC for the treatment of chronic pain and heart therapies based on myrcene-containing complex mixtures (“MCCM”).
The current US opioid epidemic, along with growing public and government concern regarding opioid abuse, makes new pain treatments a promising field of research and development. Our novel pain formulations are also substantially free of delta-9 tetrahydrocannabinol (“THC”), which minimizes their potential for abuse. Pain management represents an estimated health burden of between $560 to $650 billion dollars for chronic pain and between $17 to $20 billion dollars for immunological/neuropathic pain in the US alone. In addition, our novel heart disease formulations address the $316 billion dollar heart therapy market in the US.
Our current drug discovery efforts were accelerated through the powerful combination of GB Sciences’ proprietary in silico prediction approach, termed the GB Sciences’ Network Pharmacology Platform (“NPP”), and GB Sciences’ proven high-throughput screening techniques using cell-based models. The current provisional patent application covers myrcene-containing complex mixtures capable of targeting the non-traditional cannabinoid receptor, TRPV1. Our latest patent application complements the issued TRPV1 patent that GB Sciences licensed from Makai Biotechnology in December of 2016.
We have a Monster Pick Coming. Subscribe Right Now!
Currently moving up over $0.20 support GBLX has little assets or debt and no revenues to date. But this is an exciting story developing in small caps; the Company has developed state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis. We will be updating on GBLX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GBLX.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in GBLX either long or short and we have not been compensated for this article.